O slideshow foi denunciado.
Seu SlideShare está sendo baixado. ×

Targeting lipids: a primary and secondary care perspective

Próximos SlideShares
Carregando em…3

Confira estes a seguir

1 de 76 Anúncio

Targeting lipids: a primary and secondary care perspective

Baixar para ler offline

Presentations by Dr Sue Kemsley and Dr Gavin Galasko from the first webinar of the Mastering Cholesterol webinar series on Thursday 26 January 2023, focusing on lipid management from a primary and secondary care perspective.

Presentations by Dr Sue Kemsley and Dr Gavin Galasko from the first webinar of the Mastering Cholesterol webinar series on Thursday 26 January 2023, focusing on lipid management from a primary and secondary care perspective.


Mais Conteúdo rRelacionado

Semelhante a Targeting lipids: a primary and secondary care perspective (20)

Mais de Innovation Agency (20)


Mais recentes (20)

Targeting lipids: a primary and secondary care perspective

  1. 1. Welcome! Mastering cholesterol to optimise CVD prevention – Targeting lipids: A primary and secondary care perspective Please note this session will be recorded MUTE BUTTON Attendees’ microphones will be automatically muted, to minimise background noise. QUESTIONS Please use the Q&A button to submit questions. These will be addressed during the Q&A session.
  2. 2. Introducing Lipids: A Primary Care Approach Dr Sue Kemsley GP Primary Care Lipid Lead for Innovation Agency (AHSN NWC) Primary Care Co-Lead for C&M Strategic Cardiac Network GPwSI Cardiology
  3. 3. LDL-C causes atherosclerosis; a disease process directly causing ASCVD & CVD events CVD EVENTS LDL-C
  4. 4. ABC of CVD Prevention Atrial Fibrillation Blood Pressure Cholesterol
  5. 5. Optimising statins predicted to save over £700m in 5 years
  6. 6. NHS CVD Prevention Recovery • 25% of all UK deaths • Largest cause of premature deaths in deprived areas • NHS Long Term Plan: Single biggest area where NHS can save lives in next 10 years ASCVD
  7. 7. NHS CVD Prevention Recovery For every 1 mmol/L reduction in LDL-C, there is a reduction in annual CVD risk of 28%. National ambitions for cholesterol state by 2029: 75% of 40–74-year-olds will have a CVD risk assessment & cholesterol reading recorded on a primary care data system in the last five years 45% of 40–74-year-olds with => 20% 10-year risk of developing CVD in primary care are treated with statins And by 2024: 25% of people with Familial Hypercholesterolaemia (FH) are diagnosed and treated optimally according to NICE FH guidance
  8. 8. Why should primary care focus on lipids now? PCN DES & IIF Targets 2022: CVD risk & FH detection New guidance & clinical targets: NHS Lipid Pathway and Statin Intolerance Pathway Multidrug approach to lipids: Statins, Ezetimibe, Bempedoic acid, Inclisiran, PCSK9i and Vazkepa
  9. 9. Why are we not managing lipids better? • Lipid disorders not perceived as causing a disease process • Lipids often thought difficult to treat so why bother? • Bad press for lipid medications • Statin "side effects”, statin reluctance and nocebo effect • Often poor compliance • Confusion over guidance and treatment targets • Often tagged on to a consultations in primary care with multiple issues making a difficult conversation unmanageable • Clinician and patient inertia
  10. 10. Aims Who should have a cholesterol test and when Discuss the range of treatment options The NHS Lipid Pathway as a lipid therapy decision aid The statin intolerance pathway to address side effects How to work at scale to optimise lipid therapies
  11. 11. Primary Prevention <=84yrs & QRISK=>10% T2DM & QRISK=>10% T1DM (plus risk factor*) CKD eGFR<60 and/or albuminuria All age >84 (consider frailty etc) Secondary Prevention All ASCVD (MI/angina/revascularisation TIA/stoke/PAD) When to think lipid intervention in primary care? Familial Hyperlipidaemia
  12. 12. Chronic Long Term Condition Reviews • All ASVCD • Coronary artery disease: Angina, MI, CABG, stent • Cerebrovascular disease: stroke, TIA • Peripheral arterial disease including AAA • Genetic or suspected diagnosis of FH • Hypertension • AF • Diabetes • CKD • All 84+ years! (but tailor this to the individual) • CVD risk >10% • Other chronic diseases e.g. COPD, inflammatory disease, severe psoriasis When to think lipid therapies? Who is high risk?
  13. 13. 40-74 Years NHS Health Check • Currently only around 45% of eligible patients have an NHS health check • Only eligible if fit and well • Not eligible if, • ASVCD • HTN • AF • Heart failure • Diagnosis of FH • Diagnosis of CVD risk >10% & already on lipid therapy • Treat if QRISK>10% When to consider lipid disorders in primary care? Finding high risk undiagnosed patients
  14. 14. Familial Hypercholesterolaemia • Think identification • Refer for genetic and cascade testing • Do not use QRISK • 50% reduction in non-HDL-C
  15. 15. PCN DES & GP data searches • Age <=29 total cholesterol >7.5 • Age >=30 total cholesterol >9.0 • UCLP Lipids search 18-39 Years • Single lipid profile to consider FH • Point of care test Childhood • 12 month heel-prick test • Genetic testing if high • Family cascade testing if baby has positive results • Lifestyle advice for ALL families Finding familial hypercholesterolaemia in primary care
  16. 16. Suspected heterozygous FH diagnosis Fasting lipid profile Criteria levels more accurate for people <30 years Criteria levels increase as people get older • Adult <30 years: Fasting TC >7.5 and/or LDL-C >4.9 and/or non-HDL-C >5.9 • Child <16 years: Fasting TC >6.7 and/or LDL-C >4.0 • Anyone with TC>9.0mmol/L and/or LDL-C >6.5mmol/L and/or non-HDL-C >7.5mmol/L or fasting triglycerides > 10mmol/L Especially if; personal and/or family history of confirmed CHD (<60 years) and with no secondary causes Refer to diagnose FH if severe Hyperlipidemia, and especially if; Use FH risk calculator
  17. 17. Suspected homozygous FH diagnosis Adult under 30 years: LDL-C >13 Child under16 years: LDL-C >11
  18. 18. CM.FHS@nhs.net / 0151 254 3248 • Pilot service April 22-Sept 23 with aim to become a fully commissioned long term service. • Service aim: Identify individuals across C&M who are at risk of FH. The 1:250 incidence equates to 10,000 people. • Specialist nurse-led with paediatric and adult training. Lipidologist clinical lead. • Remote consultations provide counselling, support and genetic testing to confirm and discuss FH diagnosis and provide detailed patient information to support effective treatment with lipid therapies. • Cascade genetic testing for family members. • All referrals welcome via referral form available in EMIS (includes Welsh Lipid Score) • FH team are supporting education in the region through a series of webinars, drop-in meetings (MS Teams) and tailored educational sessions
  19. 19. Treatment Options
  20. 20. Lipid Therapies Statins • 40-50% LDL-C reduction • LFT baseline, each titration, 12 months and then not again if normal • Need to manage “intolerance” Ezetimibe • Add on to statin with additional 24% LDL-C reduction, or monotherapy • No monitoring • Well tolerated Bempedoic acid • Add on to Ezetimibe monotherapy with additional 28% LDL-C reduction • Only need to monitor renal/liver function if severe impairment Inclisiran • ASCVD after max statin ± Ezetemibe • Additional 50% LDL-C reduction • Twice yearly injection • Can be administered in primary care PCSK9i • ASCVD and/or FH • 25-75% LDL-C reduction • 2 weekly self injector • Secondary care only Vazkepa • Add on therapy to reduce triglycerides • Included in updated NHS Lipid Pathway Dec 2022
  21. 21. NHS Lipid Pathway
  22. 22. Statin Intensity
  23. 23. Ezetimibe, Bempedoic Acid, Inclisiran & PCSK9i Secondary Prevention Only (*FH)
  24. 24. Eligibility criteria for injectables If non-HDL-C >2.5 check fasting lipid profile to check LDL-C to determine eligibility. (Could consider use of equation to calculate LDL-C equivalent.) Inclisiran may be used if fasting LDL-C (or equivalent) =>2.6 PCSK9i Without CVD High risk Very high risk Not FH Not indicated LDL-C >4.0 LDL-C >3.5 FH LDL-C >5.0 LDL-C>3.5
  25. 25. Statin Reluctance Nocebo effect
  26. 26. Summary of when to check a blood test for lipid profile • Any age to assess risk of FH if no previous assessment, • Assess CVD risk for primary prevention in patients 40-74 years 5 yearly (NHS health check) • Check treatment to target (non-HDL-C <= 2.5) for ALL on lipid therapies annually (Except FH>50% reduction from baseline) • Reassess CVD risk when treating new diagnosis of diabetes or hypothyroidism or significant lifestyle interventions Random lipids if, • Significantly raised triglycerides • Patient with ASCVD being considered for Inclisiran • Patient with FH being considered for PCSK9i Fasting lipids if,
  27. 27. Optimising Lipids at Scale
  28. 28. Using Digital Tools: UCLP Framework Secondary Prevention Stratification Primary Prevention Stratification
  29. 29. UCLP secondary prevention lipid search run across all practices in PCN PCN care co-ordinator ensures up to date blood tests and offers lipid review to patients in order from UCLP groups 1, 2, and 3 in a Clinical Pharmacist/ANP clinic Prescriber-led clinic optimises oral lipid therapy according to the NHS lipid pathway and statin intolerance pathway with lifestyle counselling Patients identified as eligible for Inclisiran if not to target following optimisation of oral therapies Inclisiran clinic with care co-ordinator recall system for 3-month and 6-month injections Initial weekly MDT for advice and support FH suspects referred to lipid clinic PCN approach to optimising lipid therapies
  30. 30. Summary: Lipid disorders in primary care Case finding and MECC for lipid disorders including FH Multi drug approach Manage statin intolerance Treat to target Consider pathways to optimise at scale
  31. 31. Maximise prevention by optimising all CVD risks CVD risk Lifestyle Atrial Fibrillation Blood pressure Cholesterol Diabetes CKD Inflammatory Disease Heart failure Ethnicity Family history Age & sex
  32. 32. Thank you
  34. 34. Who should secondary care treat with lipid lowering therapy and how?  Lipid lowering guidelines  NICE clinical guideline 181 [Lipid Modification for 1o and 2o prevention], July 2014 (currently being updated)  NICE approved NHS/Accelerated Access Collaborative Guideline (lipid pathway), Dec 2022  AHSN Lipid Optimisation Pathway following acute cardiovascular event, Nov 2022  NICE clinical guideline 71 [Familial Hypercholesterolaemia], Aug 2008
  35. 35. NHS/AAC Lipid pathway p1
  36. 36. NHS/AAC Lipid pathway p2
  37. 37. AHSN Lipid optimisation pathway following acute cardiovascular event
  38. 38. Primary prevention
  39. 39. Assessment and diagnosis  For primary prevention of CVD in primary care, a systematic strategy should be used to identify people likely to be at high risk of CVD (≥10%,10 yr risk)  Use QRISK2/3 risk assessment tool to assess CVD risk for primary prevention in people 40-84 years of age  Consider FH (familial hypercholesterolaemia) if chol >7.5mM (especially if family history of premature CVD)  Do not use risk assessment tool in people with eGFR < 60 ml/min/1.73m2 and/or albuminuria  Do not use risk score in patients with proven CHD, ischaemic stroke, type 1 DM, PVD, familial ↑ lipidaemia  Treat secondary causes of dyslipidaemia first  E.g. nephrotic syn/DM/↑EtoH/dTFTs/medications eg steroids/biliary obstruction/pregnancy
  40. 40. Key assessments/advice  Smoking status  Alcohol consumption  Blood pressure  BMI or other measure of obesity  U&Es and eGFR, LFTs  Total Chol, non-HDL chol, HDL and triglycerides  HbA1c  TSH  Recommend healthy lifestyle changes
  41. 41. Statins  After managing modifiable RFs, if still appropriate and after informed discussion start Atorvastatin 20mg od  Measure full non-fasting lipid profile after 3 months  Target: >40% reduction in non-HDL cholesterol  If not achieved discuss adherence, diet, lifestyle  If at higher risk consider increasing dose up to 80mg  If still not achieved consider adding Ezetimibe 10mg od  Annual review to ensure ongoing adherence
  42. 42. Diabetes  Use QRISK2 risk assessment tool to assess CVD in people with type 2 diabetes  Offer Atorvastatin 20mg for those with ≥10% 10-year risk of developing CVD  Offer Atorvastatin 20mg for primary prevention of CVD for adults with type 1 DM who:  Are >40 or  Have had type I DM for >10 years or  Have established nephropathy or  Have other CVD risk factors  Consider Atorvastatin 20 mg for all adults with type 1 diabetes
  43. 43. Renal Failure  Offer Atorvastatin 20mg for 1o and 2o prevention of CVD  Increase dose if a >40% ↓ in non-HDL chol is not achieved (total chol – HDL-chol)  Discuss use of higher doses with renal specialist if eGFR is <30ml/min/1.73m2
  44. 44. Secondary prevention
  45. 45. Statins  Offer statin therapy to patients with acute or established CVD (CHD, PVD, ischaemic CVA). Take lipid sample within 24o of admission  Address all modifiable risk factors – smoking, diet, BP, DM, obesity etc  Initiate treatment with Atorvastatin 80mg od  Use a lower dose if:  Potential drug interactions  High risk of adverse events  Patient preference  Reassess lipid profile after 3 months high-intensity statin and see if target reached (non-HDL chol ↓ >40%)  If target not reached;  Discuss adherence and timing of dose  Optimise adherence to diet and lifestyle measures  Consider increasing dose if started on <80mg Atorvastatin  Consider role of other NICE-approved agents;  Ezetimibe/Bempedoic acid/Inclisiran/PCSK9 inhibitors/Icosapent ethyl
  46. 46. Pre-statin advice  Before offering statin, ask about persistent generalised muscle pains. If yes, measure CK  If CK > 5xULN do not start statin  If CK 1-5x ULN start at a lower dose  Advise that if they develop muscle symptoms (pain, tenderness or weakness) seek medical advice and measure CK levels  Statins are contraindicated in pregnancy (potential teratogenic risk) so stop them if pregnancy possible
  47. 47. Statins follow up  Measure total, HDL and non-HDL chol in all people who have been started on high intensity statin treatment at 3 months (non-fasting)  Provide annual medication reviews  Discuss medicine adherence, lifestyle modification and address CVD risk factors  Consider annual non-fasting blood test for non-HDL cholesterol  Do not measure CK levels routinely  Do measure CK levels if muscle symptoms occur (pain, tenderness, weakness)
  48. 48. Monitoring patients on statins  Baseline liver enzymes should be measured before starting statin. LFTs should then be measured within 3 months and at 12 months, but not again unless clinically indicated  People with ↑transaminases but <3xULN should not be excluded from statin use  If an unexplained peripheral neuropathy develops then stop statin and seek specialist advice
  49. 49. Statin therapy alternatives NICE CG 181: Lipid modification July 2014  For primary or secondary prevention of CVD, or in CKD or Type 1 DM, do not offer:  Nicotinic acid (Niacin)  Anion exchange resins  Omega-3 fatty acid compounds  Do not routinely offer fibrates (sometimes used in specialist lipid clinics)  People with primary hypercholesterolaemia should be considered for Ezetimibe in line with NICE TA 132+385 guidance  (acts synergistically with statins: ↓ intestinal cholesterol absorption vs statins ↓ chol production)  10-20% reduction in LDL-C
  50. 50. Treatment option 0 -5 -10 -15 -20 -25 -30 Baseline % LDL-C reduction from baseline In a randomised, multicentre, double-blind, parallel- group study that measured % change from baseline in LDL-C after 6 weeks’ treatment. (n=579) Up titrating to 80 mg of atorvastatin Atorvastatin 40 mg plus 10 mg of ezetimibe % LDL-C reduction from baseline 11% 27% 1. Leiter LA et al. Am J Cardiol 2008; 102(11): 1495–1501. P<0.001 Ezetimibe Adding 10mg to Atorvastatin 40mg superior to ↑ Atorv. to 80mg
  51. 51. Bempedoic acid  NICE TA 694 approved, April ‘21, 180mg od  Adenosine triphosphate citrate lyase (ACL) inhibitor which inhibits cholesterol synthesis in the liver, thereby lowering LDL-C  Always recommended with Ezetimibe and only if:  Statins contraindicated or not tolerated  Ezetimibe monotherapy does not hit target  Agreed company pricing structure adhered to (confidential)  c15% reduction in LDL-C  SEs: ↑LFTs, ↑uric acid/gout, joint pains
  52. 52. Inclisiran  NICE TA 733 approved, Oct ’21  284 mg Inclisiran in 1.5ml solution, subcutaneous dose  Give after 3 months then 6 monthly (2x/yr)  Small interfering RNA (siRNA) that ↑LDLRs via interference of PCSK- 9 production  Secondary prevention only (CHD, ischaemic stroke, PVD) and LDL-C ≥2.6mM  Must be on maximum tolerated statin ± Ezetemibe  Lowers LDL-C by approx. 50%  Can be prescribed in primary and secondary care
  53. 53. PCSK9 inhibitors  Monoclonal antibodies that inactivate proprotein convertase subtilisin- kexin type 9 (PCSK9)  Alirocumab (Praluent) and Evolocumab (Repatha)  Increase LDL-receptors on the surface of hepatocytes  ↑uptake/degradation of LDL by liver  Given by fortnightly subcutaneous injections (75-150 or 140mg)   Dramatic ↓LDL and ↓Non-HDL chol levels (50-60% reductions)  Act synergistically with statins  Statins reduce cholesterol synthesis + ↑ hepatocyte LDL-receptor levels  but increase PCSK9 levels (which act to reduce LDL-receptor levels)  Main role in FH, but role in non-FH 2o prevention  MMGs red coding (hospital prescription only)
  54. 54. NICE PCSK9 inhibitor guidance NICE TA 393 + TA 394, 2016
  55. 55. Icosapent ethyl (Vazkepa)  NICE TA 805 approved, July ’22  Stable ethyl ester of omega-3 fatty acid  Mechanism of action not fully understood  998mg capsules, 2xbd  Secondary prevention (CHD, ischaemic stroke, PVD) or DM and at least one other risk factor  Must be on statin therapy  Must have: LDL-C 1.04-2.6mM + TG≥1.7mM  ↓TG c20%, ↓non-HDL-C c10-15%  SEs: ↑bleeding time, AF, constipation, MSk pains  Can be prescribed in primary + secondary care
  56. 56. Familial Hypercholesterolaemia Nice Guidelines (CG71), 2008 (last updated Nov 2017)
  57. 57. Very common - frequency ~1/300-500 > 120,000 in UK Often underdiagnosed < 15,000 cases known in 2008 (12.5%) Very High CHD event rates untreated 0 20000 40000 60000 80000 100000 120000 140000 2000 2004 2008 2012 2016 2020 Number FH known Survey UK Lipid Clinics Missing >85% of predicted Marks, et al 2004 HEARTUK 2008 Neil, et al BMJ 2000 How common is FH? Age (years) ♂ % CHD ♀ % CHD <30 5 0 30-39 22 2 40-49 48 7 50-59 80 51 60-69 100 75 Slack, Lancet.1969;1380-2 Natural History
  58. 58. Diagnosing FH (NICE CG 71)  Consider FH in adults with total cholesterol >7.5mM, especially if there is a family history of premature CHD  Exclude secondary causes of hyperlipidaemia  Use the Simon Broome Criteria for diagnosis (can also use Dutch Lipid Clinic Network Score)  Absence of clinical signs (e.g. tendon xanthomata) does not exclude the diagnosis  Take two fasting LDL-C measurements to confirm diagnosis
  59. 59. Simon Broome Diagnostic Criteria Definite FH:  TC > 6.7 mmol/l or LDL-C >4.0 mmol/l (child <16y) or TC > 7.5 mmol/l or LDL-C >4.9 mmol/l (adult) plus one of:  tendon xanthomas in patient, or in 10 relative (parent, sibling, child), or in 20 relative (grandparent, uncle, aunt), or  DNA-based evidence of an LDL receptor mutation, familial defective apo B-100, or a PCSK9 mutation. Possible FH is defined as the above lipid cut-offs plus one of:  family history of myocardial infarction: below age of 50 years in 20 relative or below age 60 years in 10 relative, or  family history of raised TC >7.5 mmol/l in adult 10 or 20 relative or > 6.7 mmol/l in child or sibling <16y
  60. 60. Xanthomata Xanthelasma Tendon Xanthomata Palmar Xanthomata Tendon Xanthomata Tuberous Xanthomata Eruptive Xanthomata
  61. 61. FH Management  Start Statin ± Ezetimibe  Onward referral to lipid clinic:  For confirmation of diagnosis ± cascade testing  For consideration of PCSK9i therapy  Known FH who fail to achieve a reduction of LDL-C from baseline of >50% despite maximum tolerated dose of statin + ezetimibe  Young people with FH should be referred to paediatric FH specialist. Therapy to be considered from age 10  Any adult with FH at very high risk of a coronary event  Established coronary disease  A family history of premature coronary disease  Two or more other cardiovascular risk factors
  62. 62. Blackpool Lipid Clinic (established October 2018)
  63. 63. The team  Marie Wilcock - Advanced Nurse Practitioner  Dr Gavin Galasko – Consultant Cardiologist  Dr Tawfiq Choudhury – Consultant Cardiologist  Noel Topping – Cardiac Pharmacist  Clinical Biochemist due to start shortly  2018/19 – 1 monthly clinic  2022 – 4-5 clinics per week plus weekly MDT
  64. 64. Referral criteria 1. Possible Familial Hypercholesterolaemia (FH): Pre-treatment total chol >7.5mM and either a family history of myocardial infarction at age < 50-60 years or a family history of FH (Simon Broome) 2. Unexplained severe hyperlipidaemia without a family history Total chol > 9mM, or fasting LDL chol >6.5mM, or non-HDL chol > 7.5mM, or fasting triglycerides > 10mM (once other causes excluded e.g. EtOH/TFT) 3. Secondary prevention: In patients with established CVD (ischaemic stroke/TIA, PVD, ACS, coronary revascularisation) refer if total chol >6mM or fasting LDL chol >4mM despite best-tolerated lipid-lowering therapy, or if statin intolerant Suggested Investigations Prior to Referral: FBC, Biochemical profile, ALT/AST, TSH and fasting lipid profile
  65. 65. Demographics to date Year Mean age (years) Average max chol (when known) Range of chol levels Proportion with max ≥7.5mM 2019 54.9 8.9mM 5.5 - 14mM 87% 2020 57.0 9.0mM 5.6 - 19.5mM 87% 2021 54.2 9.1mM 5.5 - 14mM 89% 2022 54.5 8.7mM 3.1 – 20mM 81%
  66. 66. Genetic Testing for FH 2021/22  Testing of referred patients for FH  Criteria used:  Simon Broome criteria for possible FH  Dutch lipid score for probable FH (score ≥6)  Welsh score  26 patients found to have FH on genetic testing  16/110 new FH cases found (15% pick up) (proband testing)  10/27 cases found (37% pick up) in relatives of patients with FH (cascade testing)
  67. 67. Lipid management quiz
  68. 68. Case study one  45 year old ♂ type II diabetic with hypertension  Total chol 6.5mM, LDL 3.2mM, HDL 1.0mM  Calculated 10 year QRISK 2 CVD risk of .....  What initial lipid therapy would you recommend? 1. None - dietary advice only 2. Atorvastatin 20mg od 3. Atorvastatin 80mg od 4. Alternative statin – which one 5. Statin + Ezetimibe 6. Something else 17 %
  69. 69. Case study two  55 year old ♂ with BP, T2DM, old MI, PVD  Total chol 5.0mM, LDL 2.8mM, HDL 1.0mM, on Simvastatin 40mg  Would you recommend any change in lipid therapy? 1. None - dietary advice only 2. Change to Atorvastatin 20mg od 3. Change to Atorvastatin 80mg od 4. Change to another statin and/or medication 5. Something else
  70. 70. Case study three  62 year old ♀ smoker, BP, angina  Baseline LDL-C: 4.24 mM  On Simvastatin 40mg od but experiencing muscle pains too severe to continue treatment  What alternative lipid lowering therapy might you advise? 1. Anion exchange resin eg cholestyramine 2. Nicotinic acid (Niacin) 3. Fibrate e.g. fenofibrate 4. Omega-3 fatty acid preparation 5. Alternative statin / lower dose statin 6. Ezetimibe monotherapy 7. Measure CK levels
  71. 71. Case study four  47 year old ♂ smoker  Discharged on Atorvastatin 80mg after recent NSTEMI, treated with PCI and stent  Father died of a heart attack at 51  Total chol 6.1mM, LDL-C 4.24 mM on Rx  What might you advise? 1. Addition of Omega-3 fatty acids 2. Addition of Ezetimibe 10mg od 3. Alternative statin – if so which? 4. Something else – if so what? 5. Check he is actually taking his atorvastatin 6. Refer to local lipid clinic (for assessment of possible FH and for consideration of PCSK9i)
  72. 72. Case study five  55 year old ♂ with BP, previous MI, CKD  Baseline Total chol 7.6mM, HDL 0.9mM, LDL-C: 5.5mM prior to statins (non HDL-chol ..........)  Initiated on Atorvastatin 40mg but was titrated down to 20mg od due to severe muscle pain  Currently LDL-C 3.9mM, Total chol 5.7mM, HDL 1.0mM (non HDL–chol 4.7mM -30% reduction on treatment)  Would you recommend any change in lipid therapy? 1. No change 2. Up titrate to Atorvastatin 40mg again 3. Change to Rosuvastatin 20mg od 4. Add Ezetimibe 10mg od to Atorvastatin 5. Consider FH + referral to lipid clinic if family history of IHD 6. Consider Inclisiran if LDL-C >2.6mM after adding ezetimibe 6.7mM
  73. 73. Learning points  Primary prevention: Atorvastatin 20mg  Secondary prevention: Atorvastatin 80mg  Think FH if chol > 7.5mM + FHx IHD <50/60 yrs  Aim for 40% reduction in non-HDL Chol (so pre-treatment lvls key)  Consider Ezetimibe if statin intolerant / lipid targets not achieved  Consider referral to lipid clinic if ?FH  Consider referral to lipid clinic in secondary prevention if fasting LDL persistently >4mM despite statin therapy or if statin intolerant
  74. 74. Any questions?